WEST PHARMACEUTICAL SERVICES INC — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
West Pharmaceutical Services amended and restated its technology cross-license agreement with Daikyo Seiko, Ltd. effective July 14, 2026, governing exchange of know-how and patents for pharmaceutical packaging products (closures, vials, syringes, cartridges). West retains exclusive global distribution rights for Daikyo products outside Japan (with named carve-outs); Daikyo gains non-exclusive Japan distribution rights for West products, potentially upgrading to exclusive if thresholds are met. Both agreements run 10 years with royalty payments tied to "Special Materials, Formulas, or Processes"—specific rates redacted [***]. Agreements supersede prior 2017, 2018, and 2019 versions. Specific dollar amounts, royalty percentages, and customer names are redacted as confidential.
Why this rating
Renewal and clarification of existing long-standing relationship (ongoing since 2007, amended 2013, 2017, 2018, 2019). No new material revenue streams, scope changes, or strategic pivots evident. Both parties reconfirm established distribution and IP frameworks for next decade. Routine commercial relationship maintenance, not a novel transaction. Relative to West's $15.7B market cap, ordinary continuation.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.